Skip to main content
Top
Published in: Medical Oncology 6/2020

01-06-2020 | Ultrasound | Review Article

A closer look to the new frontier of artificial intelligence in the percutaneous treatment of primary lesions of the liver

Authors: M. Citone, F. Fanelli, G. Falcone, F. Mondaini, D. Cozzi, V. Miele

Published in: Medical Oncology | Issue 6/2020

Login to get access

Abstract

The purpose of thermal ablation is induction of tumor death by means of localized hyperthermia resulting in irreversible cellular damage. Ablative therapies are well-recognized treatment modalities for HCC lesions and are considered standard of care for HCC nodules < 3 cm in diameter in patients not suitable for surgery. Effective lesion treatment rely on complete target volume ablation. Technical limitations are represented by large (> 3 cm) or multicentric nodules as well as complex nodule location and poor lesion conspicuity. Artificial Intelligence (AI) is a general term referred to computational algorithms that can analyze data and perform complex tasks otherwise prerogative of Human Intelligence. AI has a variety of application in percutaneous ablation procedures such as Navigational software, Fusion Imaging, and robot-assisted ablation tools. Those instruments represent relative innovations in the field of Interventional Oncology and promising strategies to overcome actual limitations of ablative therapy in order to increase feasibility and technical results. This work aims to review the principal application of Artificial Intelligence in the percutaneous ablation of primary lesions of the liver with special focus on how AI can impact in the treatment of HCC especially on potential advantages on the drawbacks of the conventional technique.
Literature
1.
go back to reference Galle PR. Extended abstract: management of liver cancer. Dig Dis. 2016;34:438–9.CrossRef Galle PR. Extended abstract: management of liver cancer. Dig Dis. 2016;34:438–9.CrossRef
2.
go back to reference European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.CrossRef European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.CrossRef
3.
go back to reference Kamal A, Elmoety AAA, Rostom YAM, et al. Percutaneous radiofrequency versus microwave ablation for management of hepatocellular carcinoma: a randomized controlled trial. J Gastrointest Oncol. 2019;10:562–71.CrossRef Kamal A, Elmoety AAA, Rostom YAM, et al. Percutaneous radiofrequency versus microwave ablation for management of hepatocellular carcinoma: a randomized controlled trial. J Gastrointest Oncol. 2019;10:562–71.CrossRef
10.
go back to reference Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012;57:794–802.CrossRef Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012;57:794–802.CrossRef
11.
go back to reference Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.CrossRef Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.CrossRef
12.
go back to reference Letzen B, Wang CJ, Chapiro J. The role of artificial intelligence in interventional oncology: a primer. J Vascular Interv Radiol. 2019;30(38–41):e1. Letzen B, Wang CJ, Chapiro J. The role of artificial intelligence in interventional oncology: a primer. J Vascular Interv Radiol. 2019;30(38–41):e1.
13.
go back to reference Kim J, Choi SJ, Lee SH, et al. Predicting survival using pretreatment CT for patients with hepatocellular carcinoma treated with transarterial chemoembolization: comparison of models using radiomics. AJR Am J Roentgenol. 2018;211:1026–34.CrossRef Kim J, Choi SJ, Lee SH, et al. Predicting survival using pretreatment CT for patients with hepatocellular carcinoma treated with transarterial chemoembolization: comparison of models using radiomics. AJR Am J Roentgenol. 2018;211:1026–34.CrossRef
14.
go back to reference Mauri G, Nicosia L, Varano GM, et al. Tips and tricks for a safe and effective image- guided percutaneous renal tumour ablation. Insights Imaging. 2017;8:357–63.CrossRef Mauri G, Nicosia L, Varano GM, et al. Tips and tricks for a safe and effective image- guided percutaneous renal tumour ablation. Insights Imaging. 2017;8:357–63.CrossRef
15.
go back to reference Weiss J, Hoffmann R, Clasen S. MR-guided liver interventions. Top Magn Reson Imaging. 2018;27:163–70.CrossRef Weiss J, Hoffmann R, Clasen S. MR-guided liver interventions. Top Magn Reson Imaging. 2018;27:163–70.CrossRef
16.
go back to reference Mauri G, Vova L, De Beni S, et al. Real-Time US-CT/MRI image fusion for guidance of thermal ablation of liver tumors undetectable with US: results in 295 cases. Cardiovasc Intervent Radiol. 2015;38:143–51.CrossRef Mauri G, Vova L, De Beni S, et al. Real-Time US-CT/MRI image fusion for guidance of thermal ablation of liver tumors undetectable with US: results in 295 cases. Cardiovasc Intervent Radiol. 2015;38:143–51.CrossRef
17.
go back to reference Lee MW, Kim YJ, Park HS, et al. Targeted sonography for small hepatocellular carcinoma discovered by CT or MRI: factors affecting sonographic detection. Am J Roentgenol. 2010;194:W396–400.CrossRef Lee MW, Kim YJ, Park HS, et al. Targeted sonography for small hepatocellular carcinoma discovered by CT or MRI: factors affecting sonographic detection. Am J Roentgenol. 2010;194:W396–400.CrossRef
18.
go back to reference Huang Q, Zeng Q, Long Y, et al. Fusion imaging techniques and contrast-enhanced ultrasound for thermal ablation of hepatocellular carcinoma – A prospective randomized controlled trial. Int J Hyperthermia. 2019;36:1207–15.PubMed Huang Q, Zeng Q, Long Y, et al. Fusion imaging techniques and contrast-enhanced ultrasound for thermal ablation of hepatocellular carcinoma – A prospective randomized controlled trial. Int J Hyperthermia. 2019;36:1207–15.PubMed
19.
go back to reference Jo PC, Jang HJ, Burns PN, et al. Integration of contrast-enhanced US into a multimodality approach to imaging of nodules in a cirrhotic liver: how I do it. Radiology. 2017;282:317–31.CrossRef Jo PC, Jang HJ, Burns PN, et al. Integration of contrast-enhanced US into a multimodality approach to imaging of nodules in a cirrhotic liver: how I do it. Radiology. 2017;282:317–31.CrossRef
20.
go back to reference Abi-Jaoudeh N, Kruecker J, Kadoury S, et al. Multimodality image fusion-guided procedures: technique, accuracy, and applications. Cardiovasc Intervent Radiol. 2012;35:986–98.CrossRef Abi-Jaoudeh N, Kruecker J, Kadoury S, et al. Multimodality image fusion-guided procedures: technique, accuracy, and applications. Cardiovasc Intervent Radiol. 2012;35:986–98.CrossRef
22.
go back to reference Lee DH, Lee JM. Recent advances in the image-guided tumor ablation of liver malignancies: radiofrequency ablation with multiple electrodes, real-time multimodality fusion imaging, and new energy sources. Korean J Radiol. 2018;19:545–59.CrossRef Lee DH, Lee JM. Recent advances in the image-guided tumor ablation of liver malignancies: radiofrequency ablation with multiple electrodes, real-time multimodality fusion imaging, and new energy sources. Korean J Radiol. 2018;19:545–59.CrossRef
23.
go back to reference Lee MW. Fusion imaging of real-time ultrasonography with CT or MRI for hepatic intervention. Ultrasonography. 2014;33:227–39.CrossRef Lee MW. Fusion imaging of real-time ultrasonography with CT or MRI for hepatic intervention. Ultrasonography. 2014;33:227–39.CrossRef
24.
go back to reference Ye J, Huang G, Zhang X, et al. Three-dimensional contrast-enhanced ultrasound fusion imaging predicts local tumor progression by evaluating ablative margin of radiofrequency ablation for hepatocellular carcinoma: a preliminary report. Int J Hyperthermia. 2019;36:55–64.CrossRef Ye J, Huang G, Zhang X, et al. Three-dimensional contrast-enhanced ultrasound fusion imaging predicts local tumor progression by evaluating ablative margin of radiofrequency ablation for hepatocellular carcinoma: a preliminary report. Int J Hyperthermia. 2019;36:55–64.CrossRef
25.
go back to reference Crocetti L, Lencioni R, Debeni S, See TC, Pina CD, Bartolozzi C. Targeting liver lesions for radiofrequency ablation: an experimental feasibility study using a CT-US fusion imaging system. Invest Radiol. 2008;43:33–9.CrossRef Crocetti L, Lencioni R, Debeni S, See TC, Pina CD, Bartolozzi C. Targeting liver lesions for radiofrequency ablation: an experimental feasibility study using a CT-US fusion imaging system. Invest Radiol. 2008;43:33–9.CrossRef
26.
go back to reference Song KD, Lee MW, Rhim H, et al. Fusion imaging-guided radiofrequency ablation for hepatocellular carcinomas not visible on conventional ultrasound. AJR Am J Roentgenol. 2013;201:1141–7.CrossRef Song KD, Lee MW, Rhim H, et al. Fusion imaging-guided radiofrequency ablation for hepatocellular carcinomas not visible on conventional ultrasound. AJR Am J Roentgenol. 2013;201:1141–7.CrossRef
27.
go back to reference Iezzi R, Pompili M, Posa A, et al. Combined locoregional treatment of patients with hepatocellular carcinoma: state of the art. World J Gastroenterol. 2016;22:1935–42.CrossRef Iezzi R, Pompili M, Posa A, et al. Combined locoregional treatment of patients with hepatocellular carcinoma: state of the art. World J Gastroenterol. 2016;22:1935–42.CrossRef
28.
go back to reference Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252:903–12.CrossRef Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252:903–12.CrossRef
29.
go back to reference Takahashi S, Kudo M, Chung H, et al. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology. 2007;72(Suppl 1):98–103.CrossRef Takahashi S, Kudo M, Chung H, et al. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology. 2007;72(Suppl 1):98–103.CrossRef
30.
go back to reference Song KD, Lee MW, Rhim H, et al. Percutaneous US/MRI Fusion-guided Radiofrequency Ablation for Recurrent Subcentimeter Hepatocellular Carcinoma: Technical Feasibility and Therapeutic Outcomes. Radiology. 2018;288:878–86.CrossRef Song KD, Lee MW, Rhim H, et al. Percutaneous US/MRI Fusion-guided Radiofrequency Ablation for Recurrent Subcentimeter Hepatocellular Carcinoma: Technical Feasibility and Therapeutic Outcomes. Radiology. 2018;288:878–86.CrossRef
31.
go back to reference Kim YS, Lee WJ, Rhim H, et al. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (%3e 2 and %3c 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol. 2010;195:758–65.CrossRef Kim YS, Lee WJ, Rhim H, et al. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (%3e 2 and %3c 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol. 2010;195:758–65.CrossRef
32.
go back to reference Li K, Su ZZ, Xu EJ, et al. Improvement of ablative margins by the intraoperative use of CEUS-CT/MR image fusion in hepatocellular carcinoma. BMC Cancer. 2016;16:277.CrossRef Li K, Su ZZ, Xu EJ, et al. Improvement of ablative margins by the intraoperative use of CEUS-CT/MR image fusion in hepatocellular carcinoma. BMC Cancer. 2016;16:277.CrossRef
33.
go back to reference Ahn SJ, Lee JM, Lee DH, et al. Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma. J Hepatol. 2017;66:347–54.CrossRef Ahn SJ, Lee JM, Lee DH, et al. Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma. J Hepatol. 2017;66:347–54.CrossRef
34.
go back to reference Minami Y, Kudo M. Radiofrequency ablation of hepatocellular carcinoma: a literature review. Int J Hepatol. 2011;2011:104685.CrossRef Minami Y, Kudo M. Radiofrequency ablation of hepatocellular carcinoma: a literature review. Int J Hepatol. 2011;2011:104685.CrossRef
35.
go back to reference Abdullah BJ, Yeong CH, Goh KL, et al. Robotic-assisted thermal ablation of liver tumours. Eur Radiol. 2015;25:246–57.CrossRef Abdullah BJ, Yeong CH, Goh KL, et al. Robotic-assisted thermal ablation of liver tumours. Eur Radiol. 2015;25:246–57.CrossRef
37.
go back to reference Cazzato RL, Arrigoni F, Boatta E, et al. Percutaneous management of bone metastases: state of the art, interventional strategies and joint position statement of the Italian College of MSK Radiology (ICoMSKR) and the Italian College of Interventional Radiology (ICIR). Radiol Med. 2019;124(1):34–49. https://doi.org/10.1007/s11547-018-0938-8.CrossRefPubMed Cazzato RL, Arrigoni F, Boatta E, et al. Percutaneous management of bone metastases: state of the art, interventional strategies and joint position statement of the Italian College of MSK Radiology (ICoMSKR) and the Italian College of Interventional Radiology (ICIR). Radiol Med. 2019;124(1):34–49. https://​doi.​org/​10.​1007/​s11547-018-0938-8.CrossRefPubMed
38.
go back to reference Lachenmayer A, Tinguely P, Maurer MH, et al. Stereotactic image-guided microwave ablation of hepatocellular carcinoma using a computer-assisted navigation system. Liver Int. 2019;39:1975–85.CrossRef Lachenmayer A, Tinguely P, Maurer MH, et al. Stereotactic image-guided microwave ablation of hepatocellular carcinoma using a computer-assisted navigation system. Liver Int. 2019;39:1975–85.CrossRef
39.
go back to reference Schullian P, Laimer G, Putzer D, et al. Stereotactic radiofrequency ablation of primary liver tumors in the caudate lobe. HPB (Oxford). 2019;22(3):470–8.CrossRef Schullian P, Laimer G, Putzer D, et al. Stereotactic radiofrequency ablation of primary liver tumors in the caudate lobe. HPB (Oxford). 2019;22(3):470–8.CrossRef
40.
go back to reference Abdullah BJ, Yeong CH, Goh KL, et al. Robot-assisted radiofrequency ablation of primary and secondary liver tumours: early experience. Eur Radiol. 2014;24:79–85.CrossRef Abdullah BJ, Yeong CH, Goh KL, et al. Robot-assisted radiofrequency ablation of primary and secondary liver tumours: early experience. Eur Radiol. 2014;24:79–85.CrossRef
41.
go back to reference Wallach D, Toporek G, Weber S, et al. Comparison of freehand-navigated and aiming device-navigated targeting of liver lesions. Int J Med Robot. 2014;10:35–433.CrossRef Wallach D, Toporek G, Weber S, et al. Comparison of freehand-navigated and aiming device-navigated targeting of liver lesions. Int J Med Robot. 2014;10:35–433.CrossRef
42.
go back to reference Beyer LP, Pregler B, Niessen C, et al. Robot-assisted microwave thermoablation of liver tumors: a single- center experience. Int J Comput Assist Radiol Surg. 2016;11:253–9.CrossRef Beyer LP, Pregler B, Niessen C, et al. Robot-assisted microwave thermoablation of liver tumors: a single- center experience. Int J Comput Assist Radiol Surg. 2016;11:253–9.CrossRef
43.
go back to reference Mbalisike EC, Vogl TJ, Zangos S, et al. Image-guided microwave thermoablation of hepatic tumours using novel robotic guidance: an early experience. Eur Radiol. 2015;25:454–62.CrossRef Mbalisike EC, Vogl TJ, Zangos S, et al. Image-guided microwave thermoablation of hepatic tumours using novel robotic guidance: an early experience. Eur Radiol. 2015;25:454–62.CrossRef
44.
go back to reference Xu EJ, Lv SM, Li K, et al. Immediate evaluation and guidance of liver cancer thermal ablation by three-dimensional ultrasound/contrast-enhanced ultrasound fusion imaging. Int J Hyperthermia. 2018;34:870–6.CrossRef Xu EJ, Lv SM, Li K, et al. Immediate evaluation and guidance of liver cancer thermal ablation by three-dimensional ultrasound/contrast-enhanced ultrasound fusion imaging. Int J Hyperthermia. 2018;34:870–6.CrossRef
45.
go back to reference Lim S, Lee MW, Rhim H, et al. Mistargeting after fusion imaging-guided percutaneous radiofrequency ablation of hepatocellular carcinomas. J Vasc Interv Radiol. 2014;25:307–14.CrossRef Lim S, Lee MW, Rhim H, et al. Mistargeting after fusion imaging-guided percutaneous radiofrequency ablation of hepatocellular carcinomas. J Vasc Interv Radiol. 2014;25:307–14.CrossRef
Metadata
Title
A closer look to the new frontier of artificial intelligence in the percutaneous treatment of primary lesions of the liver
Authors
M. Citone
F. Fanelli
G. Falcone
F. Mondaini
D. Cozzi
V. Miele
Publication date
01-06-2020
Publisher
Springer US
Published in
Medical Oncology / Issue 6/2020
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-020-01380-y

Other articles of this Issue 6/2020

Medical Oncology 6/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.